Company intelligence / Profile preview

NantBioScience

Culver City, California, United Statesnantworks.com ↗
Ownership
Private
Employees
~150
Development stage
Other
01

Overview

NantBioScience develops immunotherapies using molecular profiling, with promising clinical antibody results for pancreatic/colorectal cancer (including orphan drug status for its pancreatic program), active Phase 2 trials, and multi-modal clinical programs in immuno-oncology

Therapeutic areas
Oncology
Modalities
Monoclonal antibodyRecombinant proteinSmall moleculeCell therapyNanoparticle
Industry
Biotech
02

Drug pipeline

4 assets

YE-NEO-001

1

3 more assets in the full pipeline.

03

Partnerships

National Cancer Institute (NCI/NIH) — for clinical development of recombinant NK and monoclonal antibodies

Beyond the preview

Go deeper on NantBioScience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NantBioScience.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call